1. Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment. Issue 9 (September 2019) Authors: Deshmukh, V.; O'Green, A.L.; Bossard, C.; Seo, T.; Lamangan, L.; Ibanez, M.; Ghias, A.; Lai, C.; Do, L.; Cho, S.; Cahiwat, J.; Chiu, K.; Pedraza, M.; Anderson, S.; Harris, R.; Dellamary, L.; KC, S.; Barroga, C.; Melchior, B.; Tam, B. Journal: Osteoarthritis and cartilage Issue: Volume 27:Issue 9(2019) Page Start: 1347 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SM04690, A potential disease-modifying treatment for knee osteoarthritis, functions through inhibition of CLK2 and DYRK1A, novel molecular regulators of Wnt signaling, chondrogenesis, and inflammation. (April 2019) Authors: Deshmukh, V.; O'Green, A.; Bossard, C.; Seo, T.; Lamangan, L.; Ibanez, M.; Ghias, A.; Lai, C.; Do, L.; Cho, S.; Cahiwat, J.; Chiu, K.; Pedraza, M.; Yazici, Y. Journal: Osteoarthritis and cartilage Issue: Volume 27(2019)Supplement 1 Page Start: S37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗